Q3 FY22 Earnings Presentation

Table of Executive Portfolio Financial Guidance & Contents Summary Highlights Highlights Assumptions Neuroscience (continued) COVID-19 driven procedural slowdowns; share gains and strong product pipeline Neuromodulation Brain Modulation ▲ Mid-teens Strength in U.S. and China; continued roll out of Percept TM PC and SenSightTM Lead System driving meaningful share gain and LDD growth in new implant share Pain Therapies LDD ESG Appendix DTMTM SCS on the Intellis T platform Vanta™ Recharge Free SCS Mettronic Down MSD in SCS, high-teens decline in TDD due to COVID-19 related procedural slowdowns in the U.S. and Western Europe; Continued SCS share gains Y/Y driven by strong adoption of Vanta TM and IntellisTM with DTMTM SCS Percept™ PC DBS " MDT U.S. SCS procedures in calendar Q4: permanent implants declined LSD Y/Y and up HSD sequentially; trials declined MSD Y/Y and up LDD sequentially Neuroscience • Received FDA approval of SCS therapy for treating Diabetic Peripheral Neuropathy (DPN) on Intellis TM rechargeable neurostimulator and Vanta™ recharge-free neurostimulator MSD 30% Specialty Therapies Interventional Decline primarily driven by COVID-19 impact on procedures and supply chain challenges in the U.S. and EU 18 Q3 FY22 earnings presentation | February 22, 2022 51% Cranial & Spinal Technologies 19% Neuromodulation Medtronic

View entire presentation